| Literature DB >> 36147858 |
Zhaojun Mei1, Jiaqin Yuan2, Dandan Li3.
Abstract
Galacto-oligosaccharides (GOS) are oligosaccharides formed by β-galactosidase transgalactosylation. GOS is an indigestible food component that can pass through the upper gastrointestinal tract relatively intact and ferment in the colon to produce short-chain fatty acids (SCFAs) that further regulate the body's intestinal flora. GOS and other prebiotics are increasingly recognized as useful food tools for regulating the balance of colonic microbiota-human health. GOS performed well compared to other oligosaccharides in regulating gut microbiota, body immunity, and food function. This review summarizes the sources, classification, preparation methods, and biological activities of GOS, focusing on the introduction and summary of the effects of GOS on ulcerative colitis (UC), to gain a comprehensive understanding of the application of GOS.Entities:
Keywords: biological activity; galacto-oligosaccharides; prebiotics; ulcerative colitis; β-galactosidase
Year: 2022 PMID: 36147858 PMCID: PMC9485631 DOI: 10.3389/fmicb.2022.993052
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Summarize the experimental and clinical research results of GOS in the treatment of UC.
| GOS sources | Induced colitis | Intervention | Results | References |
| Commercialized GOS | Mice with 5% DSS | GOS (0.5 g/kg/d) group, GOS (0.5 g/kg/d) + DSS group | GOS attenuated DSS-induced weight loss, colon histological damage, and reduces the secretion of cytokines in colon tissue. |
|
| Commercialized GOS | Mice with DSS | GOS (400 and 800 mg/kg) + DSS group | GOS can improve DSS-induced colitis symptoms, such as weight loss, reduced colon shortening. |
|
| Enzymatic-synthesized GOS | Mice with 2% DSS | α-GOS (400 mg/kg/day) + DSS group and β-GOS (400 mg/kg/day) + DSS group | α-GOS and β-GOS could inhibit the activation of the NOD-like receptor (NLR) family member NLRP3 inflammasome-mediated inflammation. |
|
| Commercialized GOS | Smad3-deficient mice | Model group and Smad3–/– mouse were given GOS (5,000 mg/kg body weight) | GOS enhances growth of |
|
| Commercialized GOS | Rats with TNBS | GOS-1 or GOS-2 (4 g/kg/day) | GOS increased levels of |
|
| Commercialized GOS | SD rats (Rag2–/–) with | GOS (5,000 mg/day/kg) group, GOS + miR-19b inhibitor groups | GOS can prevent diarrhea and inflammation caused by Rag2 -/- rat anti- |
|
| Vegetal compounds (LA-GOS) | Mice with 2% DSS | LA-GOS (2.5 g/kg bw/day), and the treated DSS group (UC + LA-GOS) | LA-GOS alleviated histopathological damage, decreased intestinal pH, and increased the abundance of beneficial bacteria in the UC group. |
|
| Synbiotics | Patients with UC | Group was treated with the synbiotics | Synbiotics improved clinical symptoms in UC patients and decreased fecal number and fecal pH in |
|
| Commercialized GOS | Patients with UC | UC patients with the GOS (2.8 g/d) | Prebiotics did not lower clinical scores or inflammation but normalized stools. |
|
aDextran Sulfate Sodium.